|
Volume 271, Number 25,
Issue of June 21, 1996
pp. 14707-14711
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Localization of the Vinblastine-binding Site on -Tubulin*
(Received for publication, January 19, 1996, and in revised form, April 9, 1996)
Sadananda S.
Rai
and
J.
Wolff
From the Laboratory of Biochemical Pharmacology, NIDDK, National
Institutes of Health, Bethesda, Maryland 20892
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES
ABSTRACT
A fluorescent vinblastine derivative,
vinblastine-4 -anthranilate, has been shown to inhibit polymerization
of rat brain tubulin (IC50 = 4.8 µM). Binding
of the drug to tubulin increases fluorescence intensity, causes a small
emission blue shift, and has a quantum yield of 0.037. Fluorescence
increases as a function of drug concentration, with a high affinity
site and an undetermined number of lower affinity sites. Photolabeling,
by exciting the fluorescent drug-tubulin complex at the absorption
maximum of anthranilate, yields a covalent adduct confined to
-tubulin. Its formation is specific in that it is blocked by
maytansine or vinblastine. Tryptic hydrolysis identifies a single
fluorescent -peptide coinciding with residues 175-213. The
interactions between various ligands at this central portion of
-tubulin are discussed.
INTRODUCTION
Vinblastine (VLB)1 and its congeners,
dimeric indole alkaloids derived from Catharanthus
(Vinca) roseus, are highly useful drugs for
the treatment of certain malignancies. The bulk of evidence suggests
that these effects are mediated by an interaction of these drugs with
tubulin and/or microtubules. This interaction may take the form of the
following: 1) diminished microtubule dynamics by suppressing dynamic
instability at both ends of the microtubule, thus increasing the time
spent in the ``resting'' state (this occurs at a concentration of <1
µM VLB (1)); 2) inhibition of microtubule assembly or
promotion of disassembly at intermediate concentrations (2, 3, 4); and 3)
formation of spirals, tubules with splayed (protofilament) ends,
paracrystals, and other aggregates (2, 4, 5, 6, 7) at high concentrations.
In all cases, normal microtubule function is compromised.
Vinblastine can bind to dimeric tubulin, to microtubule ends, and to
certain aggregates formed by self-association of tubulin. This has led
to considerable confusion in the literature regarding the affinity
constants, which are stated to vary over several orders of magnitude.
These values are influenced by the solvent composition, protein
concentration, presence or absence of associated proteins, and method
of assay (reviewed in Refs. 4 and 7). Certain chemically unrelated
compounds such as maytansine or rhizoxin have been shown to bind to the
same site in competitive binding assays. There are also low affinity
sites. Under the conditions of this study, affinities in the
µM range have been considered the appropriate standard of
comparison.
Attempts to localize the binding site(s) for VLB to either the - or
-monomers of tubulin have met with only limited success. Indirect
evidence points to -tubulin. Thus, VLB has major effects on the
cross-linking of specific SH groups on -tubulin with the
bifunctional N,N -ethylene bis(iodoacetamide):
Cys 239-Cys 354 cross-linking is enhanced
by VLB, whereas Cys 12-Cys 201 or
Cys 211 is inhibited by VLB (8). Similarly, VLB inhibits
the hydrolysis of the exchangeable GTP bound to -tubulin (9, 10). On
the other hand, covalent binding to tubulin showed an excess of label
on -tubulin ( / 3:2 or 3:1) using either direct
photolabeling or a photosensitive adduct (11, 12, 13). In both of these
studies, however, photoactivation was carried out at low enough
wavelengths to permit irradiation of tubulin as well, thus compromising
the specificity of the reaction. Addition of a nitro group to the
photoactive label linked to the vindoline moiety of vindesine, an
active analogue of VLB, circumvented this problem, but labeling still
favored - over -tubulin.
Because of these uncertainties, we have re-examined VLB binding to
tubulin using a photosensitive derivative that absorbed outside the
protein wavelength range and that was also as small a substituent as
possible because large spacers may lead to erroneous localization in
tubulin (12). For this reason, we derivatized VLB with anthranilic acid
through an interaction with isatoic anhydride, which could bind to one
of the two available OH groups of the drug. This method has been
successfully used in adding a fluorescent label to ATP, preserving high
affinity for the ATP site (14, 15). The fluorescent adduct of VLB so
produced has both a satisfactory antimicrotubule activity and a quantum
yield sufficient to permit localization of VLB binding to
-tubulin.
MATERIALS AND METHODS
Vinblastine sulfate and trifluoroacetic acid were from
Sigma. Isatoic anhydride was from Janssen Chemica.
Excision-grade trypsin was from Calbiochem. HPLC-grade acetonitrile was
from Fisher. Rat brain tubulin was prepared as described previously
(16, 17). Where indicated, - and -tubulins were separated
according to Uppuluri et al. (18).
The synthesis of the fluorescent VLB derivative (14, 15), here called
Ant-Vin, involves the esterification of the 4 -OH (or 3-OH) group of
VLB with isatoic anhydride at pH 9.6. To 2 mg of VLB dissolved in 50%
dimethyl sulfoxide and adjusted to pH 9.8 with 0.1 M NaOH,
2 mg of solid isatoic anhydride (recrystallized from ethanol) were
added slowly with constant stirring at 38 °C, and the reaction was
continued for 2 h, maintaining the pH at 9.6. The reaction mixture
was dried and dissolved in methanol for purification in a reverse-phase
HPLC column (Vydac C18) using a linear 50-70% methanol
gradient in 0.05% aqueous trifluoroacetic acid. Absorbance measurement
at 254 nm yielded a peak at 9.8 min, well separated from unreacted VLB
or isatoic anhydride. The yield was 68% of the theoretical value. The
purified material was dried and characterized by UV, NMR, and mass
spectra. The latter yielded a mass of 930 Da (the calculated mass for
C53H63N5O10 is
930.1057).
Tubulin (1 mg) was incubated for 30 min at 37 °C with Ant-Vin, with
or without the inhibitor VLB or maytansine, and irradiated for 20 min
under 2 cm of 20% CuSO4 as described previously (12, 18).
Irradiated samples were precipitated overnight with cold acetone in a
20 °C freezer and centrifuged in a microcentrifuge at 4 °C for
20 min at 11,000 rpm. The pellet was washed once with cold acetone,
recentrifuged, and dissolved in Mes assembly buffer by sonication.
Labeled tubulin was extensively hydrolyzed for 24 h with a 1:20
trypsin/tubulin mass ratio at 37 °C in 0.05 M
NH4HCO3, pH 8.0. In some cases, half again as
much trypsin was added after 12 h. Digests were separated by HPLC
using a reverse-phase C8 column eluted with a 1-40%
gradient of acetonitrile in 0.05% aqueous trifluoroacetic acid at a
flow rate of 0.5 ml/min for 90 min. Fractions were dried in a Savant
Speedvac concentrator, dissolved in 50% acetonitrile, and assayed for
fluorescence. Measurements were carried out in a Perkin-Elmer MPF 66 spectrofluorometer in ratio mode (uncorrected). Binding parameters were
calculated from fluorescence titration experiments. Tubulin (12.5 µM) was titrated with Ant-Vin (5-160 µM),
and the increase in area under the emission curves from 390 to 580 nm
was calculated. All areas were corrected for the inner filter effect
according to the following relation: areacorrected = areaobserved·antilog((ODex + ODem)/2), where ODex and ODem are
the optical densities at excitation (330 nm) and emission wavelengths,
respectively. ODem was negligible in these experiments.
Bound Ant-Vin was calculated according to the following relation:
Ant-Vinbound = change in area/Qf (19), where
f is the molar emission area of Ant-Vin and Q is
the enhancement factor given by Q = (Amax/Ao) 1, where
Ao is the emission area for free Ant-Vin and
Amax is the maximum area when all of the drug is
bound to tubulin. The latter was determined by titrating a fixed amount
of Ant-Vin with excess tubulin and by determining the intercept of a
plot of 1/area versus 1/tubulin. Stoichiometry and binding
constants were obtained from Scatchard plots.
Polymerization of tubulin was carried out in Mes assembly buffer
with 10% dimethyl sulfoxide and 1 mM GTP at
37 °C, measuring light scattering at 400 nm in a thermostated Cary
219 spectrophotometer. This wavelength was necessitated by the
absorption of the ligand at 350 nm.
RESULTS
Properties of Ant-Vin
The VLB-anthranilate adduct, here
called Ant-Vin, yielded a mass spectrum-derived molecular mass of 930 Da, consistent with the addition of a single anthranilate to VLB. The
location of the anthranilate could be either on the 3-OH group of the
vindoline moiety of VLB or on the 4 -OH group of the
carbomethoxyvelbanamine (often incorrectly referred to as the
catharanthine) moiety of VLB as shown in Fig. 1.
Although not definitively established, we believe that the substitution
occurred at the 4 -position for the following reasons. 1) When
vindoline is reacted with isatoic anhydride, the reaction is very slow
compared with vinblastine, and the fluorescent spectrum of the product
does not resemble the vinblastine product; and 2) a fast atom
bombardment mass spectroscopy fragment containing the 4 -OH group is
not found after acylation with isatoic anhydride.
Fig. 1.
Presumptive structure of Ant-Vin. Note
that in some reports, 4 -OH is numbered 20 .
The absorption and emission spectra of Ant-Vin in Mes assembly buffer
are depicted in Fig. 2. There are two absorption maxima:
one at 265 nm ( = 18,300 M 1
cm 1) and the other with a broad peak at ~320 nm ( = 13,200 M 1 cm 1). Excitation
spectra with emission set at 445 nm yield peaks at 267 and 327 nm, and
excitation at both peaks yields similar emission peaks. The emission
maximum occurs at 441 nm (uncorrected) when excited at 330 nm. The
relative quantum yield of Ant-Vin in Mes assembly buffer is 0.037 using
0.55 for the quantum yield of quinine in 1 N sulfuric acid
as standard.
Fig. 2.
Absorption (left trace) and
emission spectra (uncorrected; right trace) of Ant-Vin in
Mes assembly buffer. Fluorescence was excited at 330 nm. The
respective concentrations were 86 and 1.2 µM.
A.U., arbitrary units.
Polymerization
The effect of Ant-Vin on the polymerization of
rat brain tubulin is compared with that of VLB in Fig.
3. Note that light scattering was measured at 400 nm
because of absorption by Ant-Vin at 350 nm, the wavelength usually
employed. In both cases (Fig. 3, A and B), there
is a gradual decrease in the rate and extent of polymerization with
increasing concentrations of the drugs. Inhibition is nearly complete
at 3 µM VLB and at 15 µM Ant-Vin under
these polymerization conditions. These changes are accompanied by a
progressive increase in the latent period for polymerization. A potency
comparison of the two drugs is depicted in Fig. 3C, which is
derived from the data of Fig. 3 (A and B).
Ant-Vin is ~7.5 times less potent against microtubule assembly than
the parent compound, with IC50 = 0.64 µM for
VLB and 4.8 µM for Ant-Vin. It is of interest that this
IC50 is lower than the binding constant (see below),
suggesting that the inhibition of polymerization is
substoichiometric.
Fig. 3.
Inhibition of tubulin polymerization by
vinblastine (A) and Ant-Vin (B). Tubulin
(2.23 mg/ml) was polymerized at 37 °C in Mes assembly buffer with
10% dimethyl sulfoxide and 1 mM GTP and with increasing
concentrations of drugs (listed on the curves in
µM) and measured in 3-mm path length cells. In
C, maximal rate data ( A400/min)
from A and B are plotted as a function of drug
concentration. Curve 1, VLB; curve 2,
Ant-Vin.
Binding of Ant-Vin to Tubulin
When Ant-Vin binds to tubulin,
an increase in fluorescence intensity is readily observed, which is
accompanied by an ~5-nm blue shift from 441 to 436 nm (Fig.
4). This is equivalent to a polarity of 25% ethanol in
water (Fig. 4, inset). The fluorescence intensity shows a
linear dependence on the ethanol concentration (0-50%) and a
progressive blue shift in max, thus demonstrating
sensitivity of the probe to the polarity of the environment.
Fig. 4.
Emission spectra (uncorrected, excited at 330 nm) of 2.7 µM Ant-Vin in Mes assembly buffer with
increasing concentrations (12.5, 24, 37.5, 50, 62.5, and 75 µM) of rat brain tubulin (from bottom to
top). The dashed line is the control; the
two highest concentrations are superimposed. The numbers are emission
maxima. Inset, solvatochromism of 0.35 µM
Ant-Vin in ethanol/water mixtures excited at 330 nm. , fluorescence
intensity; , emission maxima. A.U., arbitrary
units.
VLB binding to tubulin is difficult to separate from its effect on
tubulin aggregation (7), which, in turn, could influence Ant-Vin
binding. To our surprise, under our solvent conditions and at
Ant-Vin/tubulin mole ratios up to 25:1, no polymerization occurred as
measured by optical density at 400 nm or by 90° light scattering at
400 nm. For this reason, we felt justified in using a simple binding
model to analyze Ant-Vin binding to tubulin. As shown in Fig.
5, 12.5 µM tubulin was titrated with
increasing Ant-Vin concentrations (5-160 µM).
Fluorescence enhancement, as calculated from the area under the curves
over a wavelength range of 390-580 nm (corrected for the inner filter
effect), is presented as a function of the total Ant-Vin concentration.
What appears to be a high affinity, linear portion at low mole ratios
is followed by poorly defined lower affinity sites at higher mole
ratios. Because it is not known whether the quantum yield for all sites
is the same, it is difficult to derive accurate binding data. On the
unproved assumption that the quantum yield is the same, we have
calculated a rough affinity constant of ~40 µM for the
linear portion. Current evidence favors one high affinity VLB-binding
site (4, 7); this and our finding of a single Ant-Vin-labeled peptide
(see below) indicate a stoichiometry of ~0.9 from Scatchard analysis.
The latter is consistent with the single -peptide identified below.
Unlike colchicine fluorescence (20), no time dependence of the
fluorescence enhancement could be detected over a period of 30 min, i.e. the fluorescence at zero time and 30 min was the
same. This suggests that binding is rapid, as has previously been shown
for VLB. Under the conditions used for high affinity binding
(Ant-Vin/tubulin mole ratio = 1), all of the Ant-Vin binding can
be blocked by a 10-fold excess of maytansine, with a return of
max to the value for free Ant-Vin. At higher
Ant-Vin/dimer mole ratios, low affinity binding is seen; this appeared
to be nonspecific in that it could not be displaced by maytansine.
These sites were not further investigated.
Fig. 5.
Binding of Ant-Vin to tubulin at
25 °C. Increasing concentrations of Ant-Vin (5-160
µM) were added to 12.5 µM tubulin in Mes
assembly buffer and excited at 330 nm. Shown is the difference in the
area of the emission curves between 390 and 580 nm in the absence and
presence of tubulin (corrected for inner filter effect). Each separate
point, in many cases with replicates, is plotted as a function of the
Ant-Vin concentration. A.U., arbitrary units.
Localization of the Ant-Vin-binding Site
It has previously
been shown that photolabeling of tubulin, followed by separation of the
- and -monomers under denaturing conditions, provides a
convenient way to identify the binding monomer provided that the label
or its spacer is not so large as to displace the label to the
contralateral monomer (12). It is for this reason that we chose
anthranilate as the smallest convenient fluorophore. After binding,
irradiation, and separation of the monomers, the bulk of the label was
located on -tubulin, with a yield of ~13%. At mole ratios 3,
significant label appeared also on -tubulin. The fluorescence of the
isolated and eluted - and -monomers was measured after
irradiation with and without a 10-fold excess of maytansine, a known
competitor at the vinca site. These results are depicted in Fig.
6. Under conditions where comparisons were made at
identical protein concentrations, >90% of the labeling of -tubulin
(curve 3) was blocked by maytansine (curve 4),
whereas none of the label in the isolated -monomer (curve
1) was affected by the presence of maytansine during binding and
irradiation (curve 2). This points to the nonspecific nature
of Ant-Vin labeling of -tubulin and the specific labeling of
-tubulin.
Fig. 6.
Specificity of Ant-Vin binding to
tubulin. Ant-Vin and tubulin (at a mole ratio of 3:1) were
incubated at 37 °C for 30 min and irradiated for 20 min in the
absence or presence of a 10-fold molar excess of maytansine. The -
and -monomers were separated on a 3-mm thick denaturing gel,
electroeluted, dissolved in Mes assembly buffer for fluorescence
spectroscopy, and excited at 330 nm. Curve 1,
-Ant-Vin/tubulin (0.4 µg/ml); curve 2,
-Ant-Vin/tubulin (0.4 µg/ml) + maytansine; curve 3,
-Ant-Vin/tubulin (0.11 µg/ml); curve 4,
-Ant-Vin/tubulin (0.11 µg/ml) + maytansine. A.U.,
arbitrary units.
Initially, tryptic peptides were prepared from isolated -monomers.
However, the fluorescent peptide could be uniquely identified in
hydrolysates of the intact dimer; hence, subsequent studies were
carried out without separation of the monomers. Tryptic digests of
Ant-Vin-labeled tubulin were analyzed by reverse-phase C8
HPLC. The results are shown in Fig. 7. All peaks were
analyzed for fluorescence; two fluorescent peaks were found (labeled *
and #), which eluted at 32.97% acetonitrile and over a range of
29.4-30.4% acetonitrile, respectively. The addition of a 5-fold molar
excess of vinblastine to the incubation mixture of Ant-Vin and tubulin
prior to photolabeling completely blocked labeling in the * fraction
(see below), whereas labeling of the other fluorescent peak (#) was not
affected by vinblastine. The * fraction was further purified on a
similar gradient of acetonitrile in 0.05% aqueous trifluoroacetic acid
on C8 columns. The * peak contained two peaks, a larger
unlabeled one that eluted at 32.32% acetonitrile and a smaller
fluorescent peak that eluted at 33.48% acetonitrile (Fig. 7,
inset). From a stoichiometry of 1, the emission yield of
Ant-Vin, and the amount of peptide present in this second peak, it can
be estimated that 50% of this material carried the label; hence, the
single peptide obtained by sequencing (see below) was unlikely to be
due to a contaminant. It is of interest that the larger peak yielded
the same amino acid sequence (see below) and thus appears to be the
unlabeled equivalent of the second peak.
Fig. 7.
Reverse-phase C8 HPLC separation
of tryptic peptides of photolabeled Ant-Vin/tubulin using a 20-40%
linear gradient of acetonitrile in 0.05% trifluoroacetic acid with a
flow rate of 0.5 ml/min for 90 min. Peaks were collected manually,
dried, and dissolved in 50% acetonitrile, and fluorescence spectra
were measured (excitation = 330 nm). * and # indicate the
only fluorescent peaks. The labeled crude peptide (*) was rerun on the
same gradient for 65 min as depicted in the inset.
Peaks 1 and 2 are the unlabeled and
fluorescently labeled peptides, respectively; they were submitted
to amino acid sequencing.
The emission spectrum of the purified isolated peptide (*) in 50%
acetonitrile, excited at 330 nm, is depicted in curve 1 in
Fig. 8. Curve 2 depicts the same purified
isolated peptide obtained after irradiation in the presence of a 5-fold
molar excess of vinblastine. This emission curve is the same as that
obtained from an indifferent unlabeled peptide; the basis for the
residual fluorescence present in these curves is unknown. When
curve 2 is subtracted from curve 1, yielding
curve 3, it is clear that vinblastine successfully competed
for the binding site of Ant-Vin. The emission maximum occurs at ~420
nm (curves 1 and 3); this should be compared with
a maximum of free Ant-Vin of 428 nm in the same solvent.
Fig. 8.
Emission spectra in 50% acetonitrile of the
purified Ant-Vin-labeled peptide (18.2 pmol) derived from -tubulin
irradiated in the absence (curve 1) and presence
(curve 2) of a 5-fold molar excess of vinblastine.
Excitation = 330 nm; slits = 5 nm. Curve 2 was
identical to a different and unlabeled peptide obtained from the
column. Curve 1 = curve 1 curve 2 and indicates that labeling of the peptide can be entirely suppressed
by excess vinblastine. A.U., arbitrary units.
N-terminal sequencing of the labeled tryptic peptide (*) and its
unlabeled partner, depicted in Fig. 7 (inset), yielded the
following sequence: Val-Ser-Asp-Thr-Val-Val-Glu-Pro-Tyr-Asn-, which
corresponds to residues 175-213 of -tubulin because the next
tryptic cut site is between Arg213 and Thr214.
The other fluorescent, but nonspecific, peptide region (#) was
sequenced, but yielded a mixture of peptides corresponding mainly to
sequences derived from -tubulin. These peptides were not further
investigated.
DISCUSSION
In this study, we present evidence that a fluorescent derivative
of vinblastine, called Ant-Vin, containing a small fluorophore at
position 4 binds in the central portion of the primary sequence of
-tubulin. Binding increases the fluorescence intensity and is
accompanied by a 5-nm blue shift. Steady-state fluorescence studies
reveal a single high affinity binding site with a KD
of ~40 µM. There are also low affinity sites whose
properties were difficult to quantify because of inner filter effects
at the high Ant-Vin concentrations and the uncertainty of their quantum
yields. Binding is specific in the sense of being inhibited by
maytansine, a vinca site analogue that blocks the binding of
vinblastine (21, 22), and we consider this reasonable evidence that
Ant-Vin binds to the vinblastine-binding site. Binding prevents tubulin
polymerization, with an IC50 of ~5 µM; but,
unlike the parent compound, Ant-Vin does not lead to aggregation, as
judged by turbidity or 90° light scattering at 400 nm with mole
ratios as large as 25:1. (The implications of this finding will be the
subject of another report.) UV irradiation at wavelengths >325 nm
leads to the formation of a covalent adduct that can be blocked by
vinblastine or maytansine. Monomer separation showed the specific label
to be confined to -tubulin. Tryptic digestion, followed by HPLC,
yielded a single fluorescent peptide spanning the region
-(175-213). Because of the low yield, the Ant-Vin-binding amino
acid could not be identified.
The central region of -tubulin is also involved in interactions with
other ligands as follows. 1) Colchicine binds at -(214-241) (18);
2) a Taxol derivative binds at -(217-231) (23); and 3) sulfhydryl
groups in this region have been shown to cross-link to other regions of
the protein, i.e.
Cys 12-Cys 201 or
Cys 211 and Cys 239-Cys 354
(8). Some of the antimitotic ligands also interact at a second locus.
Thus, colchicine also binds at the N terminus of -tubulin between
-(1-41) (18); Taxol binds in a region near Cys 12
(23), where GTP also binds (24). It is curious that GTP, one of whose
binding sites is at Cys 12, is hydrolyzed normally in the
presence of Taxol (4, 25), whereas hydrolysis is increased in the
presence of colchicine (4) and inhibited by vinblastine. Finally, the A
ring of colchicine has recently been shown to bind to
Cys 354.2 Thus, ligands at
the center of -tubulin span 11 ± 2-Å distances to both the N- and
C-terminal regions of the monomer. Surprisingly, and unlike colchicine
or Taxol, no additional contribution to the binding site from elsewhere
in -tubulin could be detected. However, Sawada et al.
(26), using an azidodansyl derivative of rhizoxin, a VLB site analogue,
located a binding component at -(363-379). Possibly, this region
may contribute to VLB binding, but was not accessible to Ant-Vin under
our conditions.
The above findings imply that some part of the central portion of
-tubulin is accessible to solvent and that the ligands bound there
may well affect each other. Such interactions occur, as we shall see
below.
1) It has been known for a long time that vinblastine and colchicine do
not hinder each other's binding. The early studies of Wilson et
al. (2, 27, 28) have repeatedly demonstrated that, by contrast,
vinblastine protects the colchicine-binding site against decay in a
number of species. This observation has been confirmed in many
laboratories (Refs. 22 and 29, 30, 31, among others). A single exception to
this consensus (32) remains unexplained. The reverse of this phenomenon
has also been shown, i.e. the decay of the high affinity
vinblastine-binding site is retarded by colchicine (33), and vinca site
compounds increase the specificity of colchicine labeling by increasing
the / labeling ratio (34).
2) Luduena and Roach (8) have shown, using the bifunctional sulfhydryl
reagent N,N -ethylene bis(iodoacetamide)
containing a 9-Å spacer, that colchicine site ligands inhibit the
formation of the cross-link between Cys 239 and
Cys 354, whereas vinca analogues enhance the formation of
this cross-link while retarding cross-linking between
Cys 12 and Cys 201 or
Cys 211. Guanine nucleotides enhance the 239/354
cross-link, while inhibiting the 12/201 or 211 cross-linking reaction.
The latter is consistent with the presence of a binding locus for GTP
at Cys 12 (24). It seems possible then that the
VLB-binding site is near enough Cys201 and/or
Cys211 to account for the blocking of cross-linking.
3) Taxol binds to tubulin with a stoichiometry of 1/dimer (35).
Depending on the location of the photolabel, binding of the derivative
occurs either at the N terminus ( -(1-31)) (23) or near the center
of the linear sequence ( -(217-231)) (36), suggesting that the
Taxol-binding site spans the distance between these regions. These
regions are near those occupied by colchicine (18) or by vinblastine as
shown here, and it is not surprising that both of these drugs inhibit
Taxol binding in cells (37) or in vitro (38). Vinblastine is
a more effective inhibitor than colchicine. However, in view of the
fact that Taxol binds preferentially to polymerized tubulin (39), a
trivial explanation may be that VLB- or colchicine-induced
conformational changes hinder the capacity of tubulin to polymerize
even in the presence of Taxol and hence reduce binding. Once stable
microtubules are formed, Taxol binding is no longer significantly
inhibited by vinblastine or colchicine (38).
Whether the interactions between the ligands are locally determined at
the central portion of the -monomer or globally or at long range, or
both, is difficult to ascertain. However, there are some examples of
probable global or long-range effects of these ligands upon each other.
Recently, it has been shown that colchicine site occupancy leads to
unfolding of an amphipathic helix near residue 390 of -tubulin as
assessed by proteolytic accessibility and that vinblastine site
occupancy prevents and/or reverses this unfolding (34, 40). Vinblastine
also enhances the fluorescence of anilinonaphthalenesulfonate when
bound to tubulin at a high affinity site (41); however, the location of
this site is not yet known. Since GTP binding is believed to be
confined to the N-terminal portion of -tubulin, some of the drug
effects on GTP hydrolysis must be considered long range with respect to
the primary structure. Finally, another long-range effect of
vinblastine is the reduced ability of the drug-tubulin complex to
interact with antibodies with different epitopes directed against
tubulin. This action is similar, but not identical, to that of
colchicine because the effects of the two drugs are additive (42). One
may conclude then that, while the folding pattern of tubulin is not
known, the central portion of the primary sequence is accessible to a
number of ligands and must also be in reasonably close proximity to
both the N terminus and a portion of the C-terminal half of the
-monomer. Which interactions between these regions of -tubulin
are mediated directly by the ligands and which are long-range
conformational effects beyond the span of these ligands remains to be
determined.
FOOTNOTES
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
``advertisement'' in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 301-496-2685;
Fax: 301-402-0240.
1
The abbreviations used are: VLB, vinblastine;
HPLC, high performance liquid chromatography; Ant-Vin,
vinblastine-4 -anthranilate; Mes,
2-(N-morpholino)ethanesulfonic acid; dansyl,
5-dimethylaminonaphthalene-1-sulfonyl.
2
E. Hamel, personal communication.
Acknowledgments
We thank Dr. Lewis Pannell for mass spectral
analyses, Leslie Knipling for generous supplies of rat brain tubulin,
and Dr. Dan Sackett for many critical discussions.
REFERENCES
-
Toso, R. J.,
Jordan, M. A.,
Farrell, K. W.,
Matsumoto, B.,
Wilson, L.
(1993)
Biochemistry
32,
1285-1293
[CrossRef][Medline]
[Order article via Infotrieve]
-
Wilson, L.,
Jordan, M. A.,
Morse, A.,
Margolis, R. L.
(1982)
J. Mol. Biol.
159,
125-149
[CrossRef][Medline]
[Order article via Infotrieve]
-
Dustin, P.
(1984)
Microtubules
, 2nd Ed.
, Springer
-Verlag,
Berlin
-
Hamel, E.
(1990)
Microtubule Proteins
(Avila, J.,
eds)
, p. 89, CRC Press
Inc., Boca Raton, FL
-
Bensch, K. G.,
Malawista, S. E.
(1969)
J. Cell Biol.
40,
95-107
[Abstract/Free Full Text]
-
Warfield, R. K. N.,
Bouck, G. B.
(1974)
Science
186,
1219-1220
[Abstract/Free Full Text]
-
Himes, R. H.
(1991)
Pharmacol. & Ther.
51,
257-267
-
Luduena, R. F.,
Roach, M. C.
(1991)
Pharmacol. & Ther.
49,
133-152
-
David-Pfeuty, T.,
Simon, C.,
Pantaloni, D.
(1979)
J. Biol. Chem.
254,
11696-11702
[Abstract/Free Full Text]
-
Lin, C. M.,
Hamel, E.
(1981)
J. Biol. Chem.
256,
9242-9245
[Abstract/Free Full Text]
-
Safa, A. R.,
Hamel, E.,
Felsted, R. L.
(1987)
Biochemistry
26,
97-102
[CrossRef][Medline]
[Order article via Infotrieve]
-
Wolff, J.,
Knipling, L.,
Cahnmann, H. J.,
Palumbo, G.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
2820-2824
[Abstract/Free Full Text]
-
Nasioulas, G.,
Grambitter, K.,
Himes, R. H.,
Ponstingl, H.
(1990)
Eur. J. Biochem.
192,
69-74
[Medline]
[Order article via Infotrieve]
-
Hiratsuka, T.
(1976)
Biochim. Biophys. Acta
453,
293-297
[Medline]
[Order article via Infotrieve]
-
Rai, S. S.,
Kasturi, S. R.
(1993)
Arch. Biochem. Biophys.
306,
133-138
[CrossRef][Medline]
[Order article via Infotrieve]
-
Sackett, D. L.,
Knipling, L.,
Wolff, J.
(1992)
Protein Expression Purif.
2,
390-393
-
Hamel, E.,
Lin, C. M.
(1984)
Biochemistry
23,
4173-4184
[CrossRef][Medline]
[Order article via Infotrieve]
-
Uppuluri, S.,
Knipling, L.,
Sackett, D. L.,
Wolff, J.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
11598-11602
[Abstract/Free Full Text]
-
Mas, M. T.,
Colman, R. F.
(1985)
Biochemistry
24,
1634-1646
[CrossRef][Medline]
[Order article via Infotrieve]
-
Bhattacharyya, B.,
Wolff, J.
(1974)
Proc. Natl. Acad. Sci. U. S. A.
71,
2627-2631
[Abstract/Free Full Text]
-
Mandelbaum-Shavit, F.,
Wolpert-De Fillipes, M. K.,
Johns, D. G.
(1976)
Biochem. Biophys. Res. Commun.
72,
47-52
[Medline]
[Order article via Infotrieve]
-
Bhattacharyya, B.,
Wolff, J.
(1977)
FEBS Lett.
75,
159-162
[CrossRef][Medline]
[Order article via Infotrieve]
-
Rao, S.,
Krauss, N. E.,
Heerding, J. M.,
Swindell, C. S.,
Ringel, I.,
Orr, G. A.,
Horwitz, S. B.
(1994)
J. Biol. Chem.
269,
3132-3134
[Abstract/Free Full Text]
-
Shivanna, B. D.,
Mejillano, R. M.,
Williams, T. D.,
Himes, R. H.
(1993)
J. Biol. Chem.
268,
127-132
[Abstract/Free Full Text]
-
Carlier, M.-F.,
Pantaloni, D.
(1983)
Biochemistry
22,
4814-4822
[CrossRef][Medline]
[Order article via Infotrieve]
-
Sawada, T.,
Kobayashi, H.,
Hashimoto, Y.,
Iwasaki, S.
(1993)
Biochem. Pharmacol.
45,
1387-1394
[CrossRef][Medline]
[Order article via Infotrieve]
-
Wilson, L.
(1970)
Biochemistry
9,
4999-5007
[CrossRef][Medline]
[Order article via Infotrieve]
-
Pfeffer, T. A.,
Asnes, C. F.,
Wilson, L.
(1976)
J. Cell Biol.
69,
599-607
[Abstract/Free Full Text]
-
Garland, D.,
Teller, D. C.
(1975)
Ann. N. Y. Acad. Sci.
253,
232-238
[CrossRef][Medline]
[Order article via Infotrieve]
-
Cortese, F.,
Bhattacharyya, B.,
Wolff, J.
(1977)
J. Biol. Chem.
252,
1134-1140
[Abstract/Free Full Text]
-
Kralovic, R. C.,
Voelz, H.
(1977)
Exp. Cell Res.
106,
205-210
[CrossRef][Medline]
[Order article via Infotrieve]
-
Prakash, V.,
Timasheff, S. N.
(1992)
Arch. Biochem. Biophys.
295,
137-145
[CrossRef][Medline]
[Order article via Infotrieve]
-
Bhattacharyya, B.,
Wolff, J.
(1976)
Proc. Natl. Acad. Sci. U. S. A.
73,
2375-2378
[Abstract/Free Full Text]
-
Sackett, D. L.
(1995)
Biochemistry
34,
7010-7019
[CrossRef][Medline]
[Order article via Infotrieve]
-
Manfredi, J. J.,
Horwitz, S. B.
(1984)
Pharmacol. & Ther.
25,
83-125
-
Rao, S.,
Orr, G. A.,
Chaudhary, A.,
Kingston, D. G. I.,
Horwitz, S. B.
(1995)
J. Biol. Chem.
270,
20235-20238
[Abstract/Free Full Text]
-
Manfredi, J. J.,
Parness, J.,
Horwitz, S. B.
(1982)
J. Cell Biol.
94,
688-692
[Abstract/Free Full Text]
-
Parness, J.,
Horwitz, S. B.
(1981)
J. Cell Biol.
91,
479-487
[Abstract/Free Full Text]
-
Sengupta, S.,
Boge, T. C.,
Georg, G. I.,
Himes, R. H.
(1995)
Biochemistry
34,
11889-11894
[CrossRef][Medline]
[Order article via Infotrieve]
-
Sackett, D. L.,
Varma, J. K.
(1994)
Biochemistry
32,
13560-13565
-
Bhattacharyya, B.,
Wolff, J.
(1975)
Arch. Biochem. Biophys.
167,
264-269
[CrossRef][Medline]
[Order article via Infotrieve]
-
Morgan, J. L.,
Spooner, B. S.
(1983)
J. Biol. Chem.
258,
13127-13133
[Abstract/Free Full Text]
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. P. Gan and M. Kavallaris
Tubulin-Targeted Drug Action: Functional Significance of Class II and Class IVb {beta}-Tubulin in Vinca Alkaloid Sensitivity
Cancer Res.,
December 1, 2008;
68(23):
9817 - 9824.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. Morris and M. N. Fornier
Microtubule Active Agents: Beyond the Taxane Frontier
Clin. Cancer Res.,
November 15, 2008;
14(22):
7167 - 7172.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Brito, Z. Yang, and C. L. Rieder
Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied
J. Cell Biol.,
August 25, 2008;
182(4):
623 - 629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. L. Henriquez, P. R. Ingram, S. P. Muench, D. W. Rice, and C. W. Roberts
Molecular Basis for Resistance of Acanthamoeba Tubulins to All Major Classes of Antitubulin Compounds
Antimicrob. Agents Chemother.,
March 1, 2008;
52(3):
1133 - 1135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Mulligan, L. M. Greene, S. Cloonan, M. M. Mc Gee, V. Onnis, G. Campiani, C. Fattorusso, M. Lawler, D. C. Williams, and D. M. Zisterer
Identification of Tubulin as the Molecular Target of Proapoptotic Pyrrolo-1,5-benzoxazepines
Mol. Pharmacol.,
July 1, 2006;
70(1):
60 - 70.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bai, D. G. Covell, G. F. Taylor, J. A. Kepler, T. D. Copeland, N. Y. Nguyen, G. R. Pettit, and E. Hamel
Direct Photoaffinity Labeling by Dolastatin 10 of the Amino-terminal Peptide of {beta}-Tubulin Containing Cysteine 12
J. Biol. Chem.,
July 16, 2004;
279(29):
30731 - 30740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Lila, T. E. Renau, L. Wilson, J. Philips, G. Natsoulis, M. J. Cope, W. J. Watkins, and J. Buysse
Molecular Basis for Fungal Selectivity of Novel Antimitotic Compounds
Antimicrob. Agents Chemother.,
July 1, 2003;
47(7):
2273 - 2282.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kavallaris, A. S. Tait, B. J. Walsh, L. He, S. B. Horwitz, M. D. Norris, and M. Haber
Multiple Microtubule Alterations Are Associated with Vinca Alkaloid Resistance in Human Leukemia Cells
Cancer Res.,
August 1, 2001;
61(15):
5803 - 5809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Chytilova, J. Macas, E. Sliwinska, S. M. Rafelski, G. M. Lambert, and D. W. Galbraith
Nuclear Dynamics in Arabidopsis thaliana
Mol. Biol. Cell,
August 1, 2000;
11(8):
2733 - 2741.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
B. Shan, J. C. Medina, E. Santha, W. P. Frankmoelle, T.-C. Chou, R. M. Learned, M. R. Narbut, D. Stott, P. Wu, J. C. Jaen, et al.
Selective, covalent modification of beta -tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors
PNAS,
May 11, 1999;
96(10):
5686 - 5691.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Rai and J. Wolff
Localization of Critical Histidyl Residues Required for Vinblastine-induced Tubulin Polymerization and for Microtubule Assembly
J. Biol. Chem.,
November 20, 1998;
273(47):
31131 - 31137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Rai and J. Wolff
The C terminus of beta -tubulin regulates vinblastine-induced tubulin polymerization
PNAS,
April 14, 1998;
95(8):
4253 - 4257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Giannakakou, D. L. Sackett, Y.-K. Kang, Z. Zhan, J. T. M. Buters, T. Fojo, and M. S. Poruchynsky
Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant beta -Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization
J. Biol. Chem.,
July 4, 1997;
272(27):
17118 - 17125.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|